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individuals. The study population was identified through a data warehouse (DENALI), 
which matches with a probabilistic linkage demographic, clinical and economic data 
of different Healthcare Administrative databases. Using DENALI we detected all sub-
jects who were hospitalized for stroke (ICD-9 CM: 430.xx-438.xx) during the period 
2000–2010. The first hospital admission date was used as index date. We estimated 
incidence, mortality and health care costs (hospitalizations, drugs and outpatient 
examinations/visits) per patient-year from the National Health Service’s perspec-
tive. Results: During the study period, around 530,000 subjects (48.3% male) expe-
rienced at least one hospital admission for stroke, corresponding to 5.2 cases on 1,000 
Lombardy inhabitants per year. Subjects had a mean (±SD) age of 74.0 (±13.2) years. 
Ischemic stroke represented the most frequent diagnosis (36.8%) followed by transient 
ischemic attack (TIA, 11.2%) and hemorrhagic stroke (9.0%). The overall mortality rate 
(x100 person-years) was 11.7, with a significant worst survival for hemorrhagic (16.7) 
and ischemic (9.1) diagnosis with respect to TIA (7.8). The average cost during the 
index year was around 6,000€ /patient-year, 10,000€ /patient-year and 20,000€ /patient-
year for TIA, ischemic and hemorrhagic stroke, respectively. For these diagnoses the 
main cost driver was represented by hospitalizations, accounting for 78%, 87% and 
94%. ConClusions: Stroke is a burdensome condition with a high mortality dis-
abilities and costs, indicating the primary importance in monitoring the developing 
of the disease from the NHS’s perspective. Administrative database analysis shows to 
be an efficient tool to accurately estimate the burden of stroke diagnoses.
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objeCtives: Long-term health and economic consequences of diabetes mellitus 
are of significant importance to health policy makers to identify the most effi-
cient interventions for disease managements. However, existing data are mainly 
from simulation models instead of “real-world” data. The objective of this study 
was to longitudinally evaluate the changes of prevalence of diabetic complica-
tions and associated health care cost in a nationally-representative longitudinal 
diabetic cohort. Methods: We used the 2000-2011 Taiwan’s Longitudinal Health 
Insurance Database (LHID) to conduct a population-based, cohort study of 136,372 
type 2 diabetic patients. Diabetic complications of each patient were calculated 
annually after the cohort entry by the adapted Diabetes Complications Severity 
Index (aDCSI) score (sum of diabetic complication with severity levels, range 0-13) 
using diagnostic codes recorded in the LHID. Study subjects were further catego-
rized into six subgroups according to their aDCSI score (0, 1, 2, 3, 4, 5+) at cohort 
entry. Health care utilizations (including outpatient and inpatient visits) as well as 
direct medical costs for the six subgroups were estimated annually using patient-
level data from the LHID. Results: We found the severity of diabetic complications 
increased over time, especially for patients with aDCSI score of 2 and above at cohort 
entry (at 10-years of follow-up: aDCSI= 0 (cohort entry), 2.37; aDCSI= 1; 3.59; aDCSI= 2; 
4.60; aDCSI= 3; 5.14; aDCSI= 4; 5.96). There were significant differences in health 
care utilizations and associated medical costs among patients stratified by aDCSI 
scores (e.g. at 1 year after cohort entry, mean counts of inpatient visits: 0.14 vs. 1.81 
for aDCSI= 0 vs.5+). Relatively high health care utilizations and associated medical 
costs in the first year of cohort entry were observed for patients with aDCSI score 
of 4 and above at cohort entry ConClusions: We provide significant evidence for 
longitudinal changes in diabetic complications and associated health care utiliza-
tion and medical costs among diabetic patients.
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objeCtives: To estimate the Brazilian supplementary health system costs of acute 
coronary syndrome (ACS), considering direct costs under the private payer perspec-
tive. Methods: Retrospective transactional-level data collection about hospitaliza-
tion costs based on claims data from a private payer perspective. Data were collected 
based on patients´ admission International Code of Disease version 10 (ICD-10) of 
Myocardial Infarction (MI) or unstable angina (UA). Index hospitalization direct costs 
were retrieved from private databases and a one year follow up was performed to 
evaluate rate of readmission and its associated costs. Patients were divided in 4 
main groups based on treatment adopted at index hospitalization: clinical treat-
ment (CT), angioplasty with stent placement (AngSt), Coronary Artery Bypass Graft 
(CABG) and Angioplasty without stent placement (Ang). Results: 2,803 hospitali-
zations were analyzed.Average age was 61 years old and 77% were men. We found 
that 85,44% underwent AngSt, 7,46% CABG, 5,6% Ang and 1,5% CT. Death rates were 
1,63%, 6,22%, 5,73%, 4,76% for AngSt, CABG, Ang and CT respectively. The average 
hospitalization costs for each group was: US$ 17,656 for AngSt, US$ 20,762 for CABG, 
US$ 15,638 for Ang and US$ 9,331 for CT. Readmission after index hospitalization 
were: 7,56%, 1,91%, 5,1% and 21,43% for AngSt, CABG, Ang and CT respectively. And 
the associated cost were US$ 13,986, US$ 12,643, US$13,000 and US$ 12,945 respec-
tively. ConClusions: AngSt is the most common treatment adopted for managing 
ACS with an average cost of US$ 17,656, followed by CABG with an average cost of 
US$ 20,762. ACS has an important economic burden for private payers that can be 
prevented. Mostly important, rehospitalization after an ACS episodemust be avoided 
due its high economic impact.
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two different sources: the unitary cost published by the Mexican Social Security 
Institute (IMSS) and the recovery cost of the General Hospital of Mexico (both with 
2013 costs). Results: The cost of treating hypoglycemic events varies according 
to severity. The main difference between the severities of hypoglycemia was in 
the hospitalization days; in mild hypoglycemia there was no hospitalization, but 
in a severe hypoglycemia it was considered 1.46 (SD±0.77) days in urgency and 
3.77(SD±1.01) days in hospitalization. In the case of the IMSS, the cost of treating a 
hypoglycemic event was US$997.81, US$1,901.78 and US$2,709.4 for mild, moder-
ate and severe hypoglycemia, while for the General Hospital case the costs were 
US$457.69, US$677.88 and US$902.22, respectively. ConClusions: The high cost 
of providing medical care to patients with hypoglycemia and its complications 
represents an economic burden to the Mexican public health care system. Currently, 
effective therapies exist for the treatment of DM2 which have a lower risk of causing 
hypoglycemic events, and consequently greater control of glucose levels. From a 
public health perspective, the use of agents with greater safety and effectiveness in 
the treatment of DM2 could avoid the high costs of treating hypoglycemic events.
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objeCtives: Although breast cancer occurs primarily among women over age 50 
years, each year more than 10,000 cases are diagnosed among women aged 18-44 
years. To date, no study has specifically quantified the economic burden of breast 
cancer in this age group in the United States. This study is the first to estimate work 
and home productivity losses due to breast cancer among younger women aged 
18-44 years. Methods: We used a two-part regression model and data from the 
2000–2010 National Health Interview Survey to estimate the number of work and 
home productivity days missed due to breast cancer, adjusted for socioeconomic 
characteristics and comorbidities. We compared our estimates for younger women 
with those of older women aged 45-64 years. Results: Per capita, younger women 
with breast cancer had annual losses of $2,293 (95% confidence interval [CI]: $1,069-
$3,518) from missed work and $288 (95% CI: $105-$471) from missed home produc-
tivity. Younger women too sick to work had annual breast cancer-attributable work 
loss costs of $365 per person (95% CI: $208-$522). In total, breast cancer-attributable 
morbidity costs for younger women were $274 million (95% CI: $128-$420 million) 
for work loss among the employed, $46 million (95% CI: $17-$75 million) for home 
productivity, and $10 million (95% CI: $6-$15 million) for work loss among women 
too sick to work. Older women with breast cancer had lower per capita work loss 
costs but higher total morbidity costs. ConClusions: Younger women with breast 
cancer face significant work and home productivity losses. These results underscore 
the importance of continued efforts by the public health community to support the 
unique needs of younger breast cancer survivors and promote prevention efforts 
throughout the lifespan.
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objeCtives: To determine and compare: 1) the incremental total costs (direct and 
indirect) for children (age 3-17 years) with and without ADHD; and 2) differences in 
the incremental direct costs for children with and without ADHD with respect to age 
groups (infants, 0-5; children, 6-11; and adolescents, 12-17 years); while controlling 
for covariates. Methods: The 2011 Medical Expenditure Panel Survey (MEPS) was 
the data source for the study. The sample consists of all children (age 0-17 years) 
with a diagnosis of ADHD (ICD9-code= 314) (Group-I) and without a diagnosis of 
ADHD (Group-II). The incremental total cost of ADHD comprised of direct expendi-
tures (prescribed medications, inpatient, ambulatory, and emergency department 
care), and the indirect costs (parents’ loss of productivity due to absence from school 
by children). A two-part model with logistic regression and a generalized linear 
model was used to estimate the incremental costs of ADHD while controlling for age, 
gender, race, Charlson co-morbidity index, family income, health insurance, usual 
source of care, area, and region. SAS 9.3 and STATA 12.0 were used for statistical 
analyses. Results: 2011 MEPS included 9838 children (age 0-17 years), of whom 
494 (5.02%) children had a diagnosis of ADHD. Group-I was 2.74 times more likely 
(CI= 1.62 to 4.62, p < 0.001) than Group-II to have an expenditure of at least $1, and, 
among children with positive expenditures, Group-I had 33% higher expenditures 
than Group-II (p = 0.001) after controlling for covariates. The incremental direct cost 
of ADHD was higher among adolescents than infants or children [$683 (p= 0.011) vs. 
$494 (p= 0.018) vs. $458 (p = 0.013)], after controlling for covariates. ConClusions: 
Children with ADHD have significantly higher costs than children without ADHD. 
Further research is needed to substantiate the high expenditures associated with 
ADHD.
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objeCtives: Stroke is a sudden loss of brain function due to inadequate blood flow 
with high impact on health status and severe prognosis. The objective of this analy-
sis was to assess incidence, mortality and economic burden of stroke from a large 
population based-study. Methods: Lombardy Region includes around 9.9 million 
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the increasing of CHADS score: 4.6, 8.9 and 18,5 for low, moderate and high stroke 
risk, respectively. The average cost during the index year was around 9,600€ /patient-
years: the main driver was represented by hospitalizations (83%), followed by drugs 
(9%). ConClusions: Administrative database analysis is an efficient tool to track 
epidemiologic and medical picture in patients with AF, which poses a significant 
burden in term of incidence, mortality and costs.
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objeCtives: The most common infections due Streptococcus pneumoniae are: otitis, 
Pneumonia, meningitis and sepsis. The aim of this study was to estimate the direct 
and indirect costs of pneumococcal diseases, in population under 5 years old in 
Colombia. Methods: Direct costs were determined from 2 sources: costs informa-
tion for 2012 from a Health Medical Organization (HMO) with national coverage and 
the construction of cases-type based on clinical practice guidelines, through bottom-
up methodology: the generating cost events were identified, validated with medi-
cal experts and valued according to tariff manual SOAT 2013. Indirect costs were 
related to mortality and sequelae caused by pneumococcal diseases. Mortality was 
estimated in terms of years of potential life lost (YPLL) based on the YPLLipc model 
(Gardner and Sanborn). Sequelae were measured in life years saved: disability-
adjusted life years and the years of life lost to premature death. The cost estimation 
was done from the perspective of third-party payer. Costs were expressed in 2013 
Colombian pesos (~1927 Colombian Peso per 1 USD). Results: Taking into account 
the HMO information, the average cost of medical attention for Acute Otitis Media 
was $150,274 per outpatient case and $1,514,030 per inpatient case, for pneumonia 
$201,969 per outpatient case and $2,238,235 per inpatient case, for meningitis and 
sepsis $371,006 per outpatient case and $7,446,978 per inpatient case, for hearing 
loss $821,857 and for mastoiditis $206,473. Taking into account the cases-type infor-
mation, the average cost of medical attention for Acute Otitis Media was $109,386 
per initial case and $890,296 per recurrent case, for pneumonia $569,643 per mild 
case and $4,310,895 per severe case, for meningitis and sepsis $10,792,183 per case, 
for hearing loss $1,323,775 and for mastoiditis $535,692. The costs of YPLL were 
$12,014,669. ConClusions: Pneumococcal diseases cause a high economic impact 
on public health resources, due the incidence of diseases.
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objeCtives: PA costs have increased during the last years, due to an increment 
in the number of affected patients. Our goal was to establish the profile and costs 
of PA in a health care plan in Brazil. Methods: We searched the HP database in 
order to identify patients with psychiatric conditions. This HP has 364 000 users. 
We identified 569 patients that received psychiatric care during a 22-month period 
(January 2012-0ctober 2013). For each patient, we identified the resources used and 
the costs associated to them. Results: Psychiatric care was responsible for 3.3% 
of all medical consultations performed in the HP and 4,955 hospitalizations, with 
a total cost of R$ 3 753 000 (US$ 1 563 000) (mean cost of R$ 4 560 (US$ 2 041) per 
patient). The most common diagnoses were substance abuse (ICD codes F10 to F19) 
and schizophrenia (ICD F20). Ancillary fees were responsible for 94% of total costs. 
Medications represented 7% of them. Antipsychotics drugs were responsible for 60% 
of the medication costs. ConClusions: PA is associated with a high cost in Brazil. 
Most costs are due to hospital fees.
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objeCtives: Chronic pain is common and persistent in the population with over 
a third of US adults affected, many with disability and quality of life issues. Pain 
management is a substantial cost burden to the health care system We sought to 
determine the prevalence and burden of pain within a large integrated health care 
delivery system in the US. Methods: Administrative databases pertaining to Henry 
Ford Health Systems (HFHS) patients were used to identify a cohort of adult persons 
with one or more of 25 pain conditions of interest in 2010 using ICD-9-CM diagnosis 
codes. Chronic pain was defined as at least two physician encounters at least 30 days 
apart. Data on prescription drug usage, hospitalizations, emergency room visits, 
physician encounters and total costs of care were obtained for a period of one year 
prior through one year after the index encounter for pain in 2010 to characterize 
resource utilization. Analyses were performed using SPS V 19.0. Results: 44% of 
persons enrolled in the health plan had at least one pain encounter with 14% meet-
ing the defined criteria for chronic pain. The conditions with the highest prevalence 
were joint pain, limb pain, and back pain. The study population also had a high 
prevalence of non-pain conditions including diabetes, chronic pulmonary disease, 
and renal disease. The overall medical costs for the patients with prevalent chronic 
pain conditions increased 24% in the post-period (average $22,639 vs. $31,692). The 
most costly conditions included diabetic neuropathy and multiple sclerosis and 
the greatest cost increases were observed for neuralgia, gout, and abdominal pain. 
Significant cost drivers included older age, presence of multiple comorbidities, and 
low body mass index. ConClusions: Chronic pain was a relatively frequent reason 
for health care service provision in HFHS and is associated with significant year-
on-year increase in medical costs.
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objeCtives: Information on costs is critical to public health policy decision-making 
about prevention strategies, but is sparse in low-income countries. We conducted a 
prospective multi-site survey of persons hospitalized in public and private facilities 
with acute respiratory infection (ARI) in northern India to estimate the costs of ARI 
episodes. Methods: Convenience samples of patients hospitalized with ARI were 
recruited at 9 public and 15 private health care facilities in the National Capital 
Region and Srinagar. Face-to-face surveys were conducted with participants upon 
admission to collect data on out-of-pocket costs of hospitalization, consultation, 
medications, diagnostics, transportation and lodging. Follow-up telephone surveys 
were conducted 2 weeks post-discharge to collect additional information including 
missed work and costs incurred after hospitalization. Out-of-pocket costs in public 
facilities were supplemented with WHO-CHOICE estimates. Missed worked days 
were valued on per capita national income (68,748 Indian Rupees). Results: During 
September, 2012-March, 2013, 452 hospitalized ARI patients were enrolled (325 in 
public and 126 in private health facilities). Median total costs of hospitalized ARI 
in public facilities was 7,633 (IQR 4, 875-13,793) Indian Rupees (INR) [US$122 (IQR 
$78-221)] and in private facilities INR 13, 598 (IQR 8,993-22,924) [US$218 (IQR $144-
367)]. The median length of stay was 7 days (IQR 5-11 days) in public facilities and 4 
days (IQR 3-5) in private facilities. The indirect cost (defined as cost of missed work 
days) accounted for 16% of total cost in private facilities and 25% in public facilities. 
Median total cost of ARI for inpatients was 11% of annual per capita income in public 
institutions and 20% in private institutions. ConClusions: ARI episodes result-
ing in hospitalizations are expensive and could be higher if more than one episode 
occurs per year. The cost and benefit of proven strategies to reduce the burden, such 
as influenza and pneumococcal vaccination should be evaluated.
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objeCtives: Urticaria is a dermatological condition characterized by a vascular 
reaction of the upper dermis. The objective of this analysis was to assess the eco-
nomic burden of urticaria from a large population based-study. Methods: The 
study population was identified through the DENALI data warehouse of the Italian 
Lombardy Region: with a probabilistic linkage DENALI matches demographic, clinical 
and economic data of different Health care Administrative databases. We detected 
all subjects who were hospitalized for idiopathic urticaria (ICD-9 CM: 708.1) or other 
specified urticaria (ICD-9 CM: 708.8) during the period 2000–2011. The first hospital 
admission date was used as index date. We estimated health care costs (hospitaliza-
tions, drugs and outpatient examinations/visits) per patients-year from the National 
Health Service’s perspective. Results: During the study period, 7,864 subjects (63.2% 
female) experienced at least one hospital admission for idiopathic urticaria or other 
specified urticaria. Subjects had a median(min-max) age of 40.9(0.0-97.1); 35.4(0.1-
97.1) and 42.4(0.0-97.1) years for idiopathic and other specified urticaria, respectively. 
The overall cost during the index year was around 2,100€ /patient-years, with no sig-
nificant differences between types of urticaria. From the 6th to the 1st year before the 
index event there was a slightly increase in costs: from 950€ /patient-years to 1,400€ /
patient-years. The overall cost remained stable for the next 5 years after the event 
(1,200€ /patient-years). Hospitalization represented the main driver of the overall cost: 
61% before, 73% during, and 53% after the index event. The most prescribed therapies 
were antihistamines for systemic use, antibacterials and corticosteroids for systemic 
use, with a peak in the month of the index event; the prescriptions of corticosteroids 
as dermatological preparation were more frequent in the month preceding the hospi-
talization. ConClusions: The economic burden of urticaria was mainly attributable 
to the index hospitalization, which led to higher costs after the index event. Detailed 
analysis are allowed by administrative data.
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objeCtives: Atrial Fibrillation (AF) is the most common type of heart rhythm disor-
der, with a prevalence of 0.5% in the adult population. It causes a significant increase 
of cardiovascular complications and reduction of long-term survival. The objective 
of this analysis was to assess the epidemiologic and economic burden of AF from 
a large population based-study. Methods: The study population was identified 
through the DENALI data warehouse of the Italian Lombardy Region: with a proba-
bilistic linkage DENALI matches demographic, clinical and economic data of dif-
ferent Health care Administrative databases. The study population was made by all 
subjects who, during the period January 2000–December 2010, were hospitalized for 
AF and flutter (ICD-9-CM: 427.3) or received ablation of heart tissue (ICD-9-CM: 37.33 
and 37.34) and/or conversion of cardiac rhythm (ICD-9-CM: 99.61,99.62, 99.69). The 
first hospital admission date was used as index date. We estimated incidence, mor-
tality and health care costs (hospitalizations, drugs and outpatient examinations/
visits) per patient-year from the National Health Service’s perspective. Results: 
During the study period, around 510,000 subjects (50.2% male) were detected, cor-
responding to 5 AF cases on 1,000 Lombardy inhabitants per year. Subjects had 
median(min-max) age of 74(0-110) years. According to the CHADS score, 62.8% and 
15.6% of the study population had a moderate and high risk of stroke, respectively. 
The overall mortality rate (x100 person-years) was 9.9, increasing significantly with 
